Abstract:Background: Osteosarcoma (OS) is commonly recognized as a malignant cancer originating from bone-forming mesenchymal stem cells, comprising approximately 20% of sarcomas. Baicalin, a bioactive flavonoid glycoside isolated from Scutellaria baicalensis, has been demonstrated to possess potent anti-inflammatory and neuroprotective properties. Objective: To explore the potential mechanisms through which baicalin exerts anti-osteosarcoma effects and facilitates osteogenesis in vitro. Methods: Cell Counting Kit-8 (CCK-8), scratch assay, and transwell assay were employed to assess the effects of baicalin at varying concentrations (20, 40, and 80 μM) on U2OS cell proliferation, invasion, and migration, respectively. Western blot and qRT-PCR analyses were conducted to evaluate the influence of baicalin on the osteogenic potential of OS cells by examining osteoblast markers such as osteocalcin (OCN), osteopontin (OPN), and runt-related transcription factor 2 (RUNX2), as well as the osteoclast marker-receptor activator of nuclear factor kappa B ligand (RANKL). Additionally, the impact of baicalin on epithelial-mesenchymal transition (EMT) markers (N-cadherin, E-cadherin, Vimentin) and proteins related to the Nuclear factor κB (NF-κB) signaling pathway (p-p65, p-IκBα, p65, IκBα) in OS cells was evaluated via western blot analysis. The activity and mineralization capacity of Alkaline Phosphatase (ALP) in baicalin-treated cells were examined through ALP staining and Alizarin Red S (ARS) staining. Results: Baicalin exhibited significant suppression of OS cell U2OS invasion (p < 0.01), migration (p < 0.01), and proliferation (p < 0.05) at various concentrations. Additionally, baicalin treatment notably increased the E-cadherin protein level, while decreasing the expression levels of Vimentin and N-cadherin proteins (p < 0.01), thus promoting EMT. Following baicalin treatment, there was a marked elevation in the protein and mRNA expression levels of RUNX2, OPN, and OCN, while the expression level of RANKL protein was reduced (p < 0.05), indicating enhanced osteogenic differentiation. The groups treated with baicalin exhibited higher ALP activity and mineralization ability (p < 0.01). Moreover, baicalin treatment significantly reduced the expression levels of p-IκBα and p-p65 proteins, as well as the ratios of p-IκBα/IκBα and p-p65/p65 (p < 0.01). These effects of baicalin were concentration-dependent, with higher concentrations yielding stronger effects. Conclusion: In vitro, baicalin demonstrates anti-OS effects and facilitates osteogenic differentiation, potentially by inhibiting NF-κB pathway activity.

Baicalein inhibits cell development, metastasis and EMT and induces apoptosis by regulating ERK signaling pathway in osteosarcoma

Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells

Baicalein Inhibits Osteosarcoma Cell Proliferation and Invasion Through the Mir‑183/ezrin Pathway.

Baicalein Inhibits Progression of Osteosarcoma Cells Through Inactivation of the Wnt/β-catenin Signaling Pathway.

Baicalein Inhibits The Invasion, Migration And Epithelial-Mesenchymal Transition Of Bgc-823 Cells Through Nf-Kappa B/Snail Signaling Pathway

Transcriptome Analysis And Characterized Differentially Regulated Genes Between Treated And Untreated Saos-2 Cells With Baicalein

Baicalein Induces Human Osteosarcoma Cell Line MG-63 Apoptosis Via ROS-induced BNIP3 Expression.

Baicalin Plays an Anti-Osteosarcoma Role in Vitro and Promotes Osteogenic Differentiation by Inhibiting NF-κB Signaling

Baicalein inhibits renal cancer cell growth and metastasis via ERK and p38 pathway

Effects of Baicalein on Proliferation, Apoptosis, Migration and Invasion of Ewing's Sarcoma Cells.

Baicalein mediates the anti-tumor activity in Osteosarcoma through lncRNA-NEF driven Wnt/β-catenin signaling regulatory axis

Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways

Baicalin Inhibits Human Osteosarcoma Cells Invasion, Metastasis, and Anoikis Resistance by Suppressing the Transforming Growth Factor-Β1-induced Epithelial-to-mesenchymal Transition

Baicalein Suppresses Metastasis of Breast Cancer Cells by Inhibiting Emt Via Downregulation of Satb1 and Wnt/Beta-Catenin Pathway

Baicalein Inhibits Growth of Cervical Carcinoma Via Inducing Apoptosis of Tumor Cells In Vivo

Icariin Inhibits Growth Of Human Osteosarcoma Cells By Inducing Apoptosis Via Downregulation Of Beta-Catenin Signaling

Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells

Baicalein Inhibits The Invasion And Metastatic Capabilities Of Hepatocellular Carcinoma Cells Via Down-Regulation Of The Erk Pathway

Baicalein Inhibits MMPs Expression via a MAPK-Dependent Mechanism in Chondrocytes.

Baicalein Induces Apoptosis and Autophagy of Breast Cancer Cells Via Inhibiting PI3K/AKT Pathway in Vivo and Vitro.

Baicalein Inhibits Prostate Cancer Cell Growth and Metastasis Via the Caveolin-1/Akt/mtor Pathway